Dylan Oatman, PA
Physician Assistant · Lincoln, NENPI 1457981599
Payments from drug & device makers
Across 206 payments — averaging $15.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$570
- Novo Nordisk$361
- Ascensia Diabetes Care US Inc.$304
- AstraZeneca$283
- Corcept Therapeutics$213
- Sanofi-aventis U.S. LLC$168
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,162100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 51 | $570 |
| Novo Nordisk | 26 | $361 |
| Ascensia Diabetes Care US Inc. | 23 | $304 |
| AstraZeneca(2 entities) | 10 | $283 |
| Corcept Therapeutics | 9 | $213 |
| Sanofi-aventis U.S. LLC | 14 | $168 |
| Amgen(2 entities) | 9 | $153 |
| Medtronic | 6 | $117 |
| Zealand Pharma US, Inc. | 7 | $116 |
| Tandem Diabetes Care, Inc. | 7 | $113 |
| Mannkind Corporation | 6 | $105 |
| Boehringer Ingelheim | 5 | $81 |
| Xeris Pharmaceuticals, Inc. | 3 | $72 |
| Recordati_rare_diseases_inc. | 3 | $57 |
| Amneal Pharmaceuticals LLC | 3 | $54 |
| Amryt Pharma Holdings Ltd | 3 | $40 |
| Antares Pharma, Inc. | 2 | $40 |
| Ultragenyx Pharmaceutical Inc. | 2 | $37 |
| Halozyme Inc | 2 | $34 |
| BETA Bionics, Inc. | 2 | $34 |
| Astellas Pharma US Inc | 1 | $28 |
| Nevro Corp. | 1 | $22 |
| Abbott | 1 | $20 |
| Eisai Inc. | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| Chiesi USA, Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Cequr Corporation | 1 | $15 |
| IBSA Pharma Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| AbbVie | 1 | $14 |
| Radius Health, Inc. | 1 | $14 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$142
How this compares
$3,174 in reported general payments places this provider in the 85th percentile of 1,127 physician assistant providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 168 | $191,559 |
| MounjaroTirzepatide | 130 | $145,629 |
| Tresiba Flextouch U-200Insulin Degludec | 106 | $121,308 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 108 | $101,589 |
| JardianceEmpagliflozin | 70 | $63,227 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 40 | $60,994 |
| TrulicityDulaglutide | 41 | $47,245 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 44 | $37,707 |
| FarxigaDapagliflozin Propanediol | 46 | $33,359 |
| Humulin R U-500Insulin Regular, Human | 12 | $32,729 |
| Tresiba Flextouch U-100Insulin Degludec | 49 | $27,679 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 15 | $20,725 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 15 | $17,975 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 16 | $16,724 |
| LyumjevInsulin Lispro-Aabc | 15 | $15,330 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog | $570 | $214,448205 claims |
| Novo NordiskOzempic, Novolog | $361 | $193,443187 claims |
| Boehringer IngelheimJardiance | $81 | $63,22770 claims |
| AstraZenecaFarxiga | $283 | $33,35946 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $168 | $17,97515 claims |
| AbbVieSynthroid | $14 | $5,78774 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $54 | $1,442152 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,127 physician assistant providers in Nebraska.
Other physician assistant in Lincoln
- Laura TvrdyLincoln$13K
- Courtney MaresLincoln$13K
- Jacklynn KmentLincoln$10K
- Bethany LambertLincoln$9K
- Kelsey WerginLincoln$8K
- Makayla DoolittleLincoln$7K
- Christina MeyerLincoln$7K
- Ashley JohnsonLincoln$7K
- Shaun RingLincoln$7K
- Katelyn EspinozaLincoln$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.